PT1531819E - Utilização de inibidores da i capa b cinase na terapia da dor - Google Patents

Utilização de inibidores da i capa b cinase na terapia da dor Download PDF

Info

Publication number
PT1531819E
PT1531819E PT03753349T PT03753349T PT1531819E PT 1531819 E PT1531819 E PT 1531819E PT 03753349 T PT03753349 T PT 03753349T PT 03753349 T PT03753349 T PT 03753349T PT 1531819 E PT1531819 E PT 1531819E
Authority
PT
Portugal
Prior art keywords
kappa
pain
treatment
kinase inhibitors
kinase
Prior art date
Application number
PT03753349T
Other languages
English (en)
Inventor
Gerhard Jaehne
Karl Rudolphi
Olaf Ritzeler
Gerd Geisslinger
Martin Michaelis
Hans-Georg Schaible
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of PT1531819E publication Critical patent/PT1531819E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Paper (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
PT03753349T 2002-08-17 2003-08-05 Utilização de inibidores da i capa b cinase na terapia da dor PT1531819E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10237723A DE10237723A1 (de) 2002-08-17 2002-08-17 Verwendung von IKappaB-Kinase Inhibitoren in der Schmerztherapie

Publications (1)

Publication Number Publication Date
PT1531819E true PT1531819E (pt) 2009-02-18

Family

ID=31968975

Family Applications (1)

Application Number Title Priority Date Filing Date
PT03753349T PT1531819E (pt) 2002-08-17 2003-08-05 Utilização de inibidores da i capa b cinase na terapia da dor

Country Status (34)

Country Link
EP (1) EP1531819B1 (pt)
JP (1) JP4504811B2 (pt)
KR (2) KR20110135428A (pt)
CN (1) CN100398107C (pt)
AR (1) AR043045A1 (pt)
AT (1) ATE418336T1 (pt)
AU (1) AU2003271555B2 (pt)
BR (1) BR0313555A (pt)
CA (1) CA2495455C (pt)
CO (1) CO5690585A2 (pt)
CR (1) CR7716A (pt)
CY (1) CY1108874T1 (pt)
DE (2) DE10237723A1 (pt)
DK (1) DK1531819T3 (pt)
EC (1) ECSP055609A (pt)
ES (1) ES2320118T3 (pt)
HK (1) HK1079426A1 (pt)
HR (1) HRP20050041B1 (pt)
IL (1) IL166780A (pt)
MA (1) MA27334A1 (pt)
MX (1) MXPA05001218A (pt)
MY (1) MY138059A (pt)
NO (1) NO334309B1 (pt)
OA (1) OA12907A (pt)
PL (1) PL212356B1 (pt)
PT (1) PT1531819E (pt)
RS (1) RS51878B (pt)
RU (1) RU2320338C2 (pt)
SI (1) SI1531819T1 (pt)
TN (1) TNSN05044A1 (pt)
TW (1) TWI325782B (pt)
UA (1) UA80837C2 (pt)
WO (1) WO2004022057A1 (pt)
ZA (1) ZA200500323B (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718644B2 (en) 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
DE10237722A1 (de) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
BRPI0511834A (pt) 2004-07-14 2008-01-08 Ptc Therapeutics Inc métodos por tratar hepatite c
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
WO2006019832A1 (en) 2004-07-22 2006-02-23 Ptc Therapeutics, Inc. Thienopyridines for treating hepatitis c
DE102005025225A1 (de) * 2005-06-01 2006-12-07 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von 2-(2-Amino-pyrimidin-4-yl)-1H-indol-5-carbonsäure-derivaten
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AR072297A1 (es) 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
JP5790440B2 (ja) * 2010-12-01 2015-10-07 住友化学株式会社 ピリミジン化合物およびその有害生物防除用途
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2532755A1 (en) * 2011-06-10 2012-12-12 Sanofi-Aventis Methods and uses based on Slfn2 expression and relating to the identification and profiling of compounds for use in the treatment or prevention of pain
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN104105483B (zh) * 2011-12-06 2017-03-22 赛诺菲 2‑(2‑甲基氨基‑嘧啶‑4‑基)‑1h‑吲哚‑5‑羧酸[(s)‑1‑氨甲酰基‑2‑(苯基‑嘧啶‑2‑基‑氨基)‑乙基]‑酰胺的晶体形式
EP3184095A1 (en) 2013-05-23 2017-06-28 IP Gesellschaft für Management mbH Administration units comprising polymorph 1 of 2-(2-methylamino-pyrimidin-4-yl]-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
US9968605B2 (en) * 2014-07-03 2018-05-15 Sanofi 2-(2-methylamino-pyrimidin-4-yl)-1h-indole-5-carboxylic acid [(S)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide for use in the treatment of pain associated to osteoarthritis
KR20210032950A (ko) 2018-07-16 2021-03-25 노파르티스 아게 페닐피페리디닐 인돌 유도체를 제조하기 위한 화학적 방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU769350B2 (en) * 1999-06-23 2004-01-22 Sanofi-Aventis Deutschland Gmbh Substituted benzimidazole
DE19951360A1 (de) * 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
DE10237722A1 (de) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase

Also Published As

Publication number Publication date
TW200417370A (en) 2004-09-16
NO334309B1 (no) 2014-02-03
OA12907A (en) 2006-10-13
CY1108874T1 (el) 2014-07-02
AU2003271555B2 (en) 2009-03-26
EP1531819B1 (de) 2008-12-24
RU2320338C2 (ru) 2008-03-27
TWI325782B (en) 2010-06-11
CA2495455A1 (en) 2004-03-18
PL373568A1 (en) 2005-09-05
RS51878B (sr) 2012-02-29
HRP20050041A2 (hr) 2006-04-30
JP4504811B2 (ja) 2010-07-14
TNSN05044A1 (en) 2007-05-14
WO2004022057A1 (de) 2004-03-18
RS20050070A (en) 2007-06-04
HRP20050041B1 (hr) 2013-07-31
ATE418336T1 (de) 2009-01-15
JP2005539053A (ja) 2005-12-22
IL166780A0 (en) 2006-01-15
AR043045A1 (es) 2005-07-13
PL212356B1 (pl) 2012-09-28
DE50310980D1 (de) 2009-02-05
MXPA05001218A (es) 2005-05-16
MY138059A (en) 2009-04-30
CN100398107C (zh) 2008-07-02
ECSP055609A (es) 2005-04-18
EP1531819A1 (de) 2005-05-25
CA2495455C (en) 2011-01-11
DE10237723A1 (de) 2004-07-08
KR20050058339A (ko) 2005-06-16
KR101119845B1 (ko) 2012-02-28
MA27334A1 (fr) 2005-05-02
DK1531819T3 (da) 2009-04-20
SI1531819T1 (sl) 2009-06-30
HK1079426A1 (en) 2006-04-07
KR20110135428A (ko) 2011-12-16
ES2320118T3 (es) 2009-05-19
BR0313555A (pt) 2005-07-12
CO5690585A2 (es) 2006-10-31
CN1674899A (zh) 2005-09-28
CR7716A (es) 2008-11-25
RU2005107419A (ru) 2005-08-10
IL166780A (en) 2011-11-30
NO20051339L (no) 2005-05-03
UA80837C2 (uk) 2007-11-12
AU2003271555A1 (en) 2004-03-29
ZA200500323B (en) 2006-02-22

Similar Documents

Publication Publication Date Title
SI1531819T1 (sl) Uporaba IxB-kinaznih inhibitorjev pri terapiji bolečin
PL374700A1 (en) Use of cytokine synthesis inhibitors for the treatment of dry eye disorders
IL209352A0 (en) 4-tetrazolyl-4phenylpiperidine derivatives for treating pain
HRP20041029A2 (en) Therapeutic use of selcetive pde10 inhibitors
HUS2200036I1 (hu) Dihidroimidazolonok alkalmazása kutyák kezelésére
SI1627639T1 (sl) Uporaba inhibitorjev COX-2 za zdravljenje afektivnih motenj
IL151890A0 (en) Hydroxyphenyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
AU2003290059A8 (en) Use of cd137 antagonists for the treatment of tumors
IL157593A0 (en) Carbamate compounds for use in the treatment of pain
GB0213869D0 (en) The treatment of pain
EP1359885A4 (en) NOS-HEMMER FOR THE TREATMENT OF WRINKLES
IL151891A0 (en) Quinolinyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
IL151765A0 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
GB0211295D0 (en) Treatment of pain
IL162818A0 (en) Combination therapy for the treatment of bacterialinfections
IL161748A0 (en) New use for the treatment of gastroesophageal reflux
GB2410744B (en) Kinase inhibitors for the treatment of disease
IL172101A0 (en) Use of indazole derivatives for the treatment of neuropathic pain
HK1087027A1 (en) Use of 2H-Ä1, 3Ü-oxazinoÄ3,2-AÜindole derivatives for the treatment of neuropathic pain
HK1062806A1 (en) Novel methods for the treatment and prevention of pain using stress- activated protein kinase inhibitors
HUP0402664A3 (en) 2-indanylamino derivatives for the therapy of chronic pain
PL370839A1 (en) Use of proton pump inhibitors for the treatment of airway disorders
GB0325957D0 (en) The treatment of pain
GB0216978D0 (en) The treatment of pain
GB0213870D0 (en) The treatment of pain conditions